Niagen Bioscience Doubles Net Income to $17.7M, Eyes $145M 2026 Revenue
Niagen Bioscience posted 2025 net sales of $129.4 million, up 30%, with net income of $17.7 million more than double prior year. CEO Rob Fried is targeting $145 million revenue in 2026 and exploring at-home NAD+ self-injection kits, acquisitions, beauty ingredient deals and pharmaceutical partnerships ahead of NOPARK trial data.
1. Full Year 2025 Results
Niagen Bioscience reported net sales of $129.4 million in 2025, a 30% increase over 2024, with net income rising to $17.7 million versus $8.6 million the prior year. The company ended the year with $64.8 million in cash and zero debt.
2. Fourth Quarter Performance
In Q4, revenue climbed 16% to $33.8 million, producing earnings of $4.1 million and $0.05 per share on an adjusted basis. The quarter’s net income compared with $7.2 million in Q4 2024, reflecting fewer one-time gains this period.
3. 2026 Guidance and Outlook
Management projects 2026 revenue of approximately $145 million, indicating about 15% growth, with a conservative forecast driven by competitive supplement market dynamics. Fried notes the company’s history of cautious guidance and expects measured expansion.
4. Strategic Expansion Initiatives
CEO Rob Fried is pursuing at-home NAD+ self-injection kits requiring prescription, actively evaluating acquisitions and negotiating beauty ingredient partnerships. The company is also in talks for pharmaceutical collaborations and anticipates NOPARK Parkinson’s trial data submission within weeks.